SANA
Sana BiotechnologyยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SANA Profile
Sana Biotechnology, Inc.
A company focused on creating and delivering engineered cells as medicines
188 East Blaine Street, Suite 400, Seattle, Washington 98102
--
Sana Biotechnology, Inc., was incorporated in Delaware on July 13, 2018. The company is developing in vitro and in vivo cell engineering platforms to revolutionize a range of therapeutic areas with unmet therapeutic needs, including oncology, diabetes, central nervous system diseases, cardiovascular diseases and genetic diseases, among others. Clinical data from the company's first project, the CD19 Targeted Alien Chimeric Antigen Receptor (CAR) T (SC 291) project, is expected to be released in 2023. The company is also making progress in developing cell engineering platforms and advancing product candidates through preclinical development, with the goal of submitting multiple investigational new drugs in 2023 and beyond.
